Form 8-K - Current report:
SEC Accession No. 0001437749-25-002474
Filing Date
2025-02-03
Accepted
2025-02-03 11:10:27
Documents
15
Period of Report
2025-01-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K krbp20250202_8k.htm   iXBRL 8-K 29730
2 EXHIBIT 10.1 ex_773527.htm EX-10.1 151262
  Complete submission text file 0001437749-25-002474.txt   351347

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA krbp-20250128.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE krbp-20250128_def.xml EX-101.DEF 11818
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE krbp-20250128_lab.xml EX-101.LAB 15883
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE krbp-20250128_pre.xml EX-101.PRE 12033
17 EXTRACTED XBRL INSTANCE DOCUMENT krbp20250202_8k_htm.xml XML 2932
Mailing Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054
Business Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054 832-968-4888
Kiromic Biopharma, Inc. (Filer) CIK: 0001792581 (see all company filings)

EIN.: 464762913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39619 | Film No.: 25580974
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)